Special Issue "Frontiers in Shigella Vaccine Development"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 August 2021.

Special Issue Editors

Dr. Duncan Steele
E-Mail Website
Guest Editor
Bill and Melinda Gates Foundation, Seattle, WA, USA
Interests: vaccines; diarrhea; enteric; rotavirus; typhoid; cholera; virus; global health
Prof. Calman A. MacLennan
E-Mail Website
Guest Editor
Bill and Melinda Gates Foundation, Seattle, WA, USA
Interests: vaccines; diarrhea; enteric; salmonella; shigella; bacteria; global health

Special Issue Information

Dear Colleagues, 

Based on the burden of Shigella infections in young children in low- and lower-middle income countries (LMICs), there has been much activity in the development of Shigella vaccines for global health vaccines in recent years. Building on the proof-of-principle from the finding of the efficacy of the early NIH S. sonnei O-antigen/tetanus toxoid conjugate vaccine from >20 years ago, new candidate O-antigen-based vaccines are progressing through early clinical trials. Two candidates, one quadrivalent and one monovalent vaccine, are currently being tested in the target population of infants in LMICs. 

In addition, there have been important advances in aligned activities that will be needed for the licensure, prequalification, and ultimately introduction of these new Shigella vaccines. These activities include the harmonization of Shigella CHIM, standardization of a Shigella ELISA, steps towards the development of a first international standard serum, development of a Shigella vaccine value proposition, exploratory of pathways to licensure and regulatory considerations, and preparation of potential sites for a phase-3 efficacy trial. 

This Special Issue titles “Frontiers in Shigella Vaccine Development” will serve to update the vaccine and infectious diseases communities on the recent progress in this area, and help provide a line of sight through to the licensure of the first global health Shigella vaccines.

Dr. Duncan Steele
Prof. Calman A. MacLennan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Shigella
  • vaccines
  • diarrhea
  • dysentery
  • bacteria
  • global health

Published Papers

This special issue is now open for submission.
Back to TopTop